Healthcare technology has become one of the most dynamic areas of global innovation, with advances in artificial intelligence, medical imaging and Data Analytics reshaping how diseases are diagnosed and managed. Companies capable of delivering meaningful clinical improvements while integrating seamlessly into existing healthcare workflows are increasingly attracting attention from investors seeking Long-term Growth opportunities.

Among emerging Australian healthcare technology companies, 4DMedical Ltd (ASX: 4DX) has built a distinctive position through its focus on respiratory imaging and functional lung analysis. The company’s proprietary technologies are designed to transform standard medical scans into advanced clinical insights, helping healthcare professionals assess lung function with greater precision.

Over recent years, 4DMedical has expanded beyond its Australian origins and established a growing presence in North America, while more recent initiatives have opened the door to Europe. Combined with expanding regulatory clearances, commercial partnerships and artificial intelligence capabilities, the company is positioning itself as a global participant in the rapidly evolving lung health market.

For investors, the key question is whether 4DMedical can successfully convert its technological advantages and growing market opportunities into a scalable commercial Business capable of delivering sustained long-term growth.

Building a Global Lung Health Technology Platform

4DMedical has evolved from a specialist respiratory imaging company into a broader healthcare technology platform focused on lung disease detection, diagnosis and monitoring.

The company's core technology suite is built around advanced imaging software that extracts functional information from conventional scans. Unlike traditional imaging approaches that primarily focus on anatomical structures, 4DMedical's solutions seek to provide clinicians with deeper insights into how the lungs are functioning.

This capability addresses a growing need within healthcare systems. Respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, lung cancer and pulmonary embolism, continue to represent major health burdens globally. Earlier diagnosis and improved monitoring can potentially support better clinical outcomes while reducing healthcare costs.

Importantly, 4DMedical operates a Software-as-a-Service (SaaS) model, allowing healthcare providers to adopt its technologies without investing in entirely new imaging infrastructure. This approach may lower barriers to adoption and support scalability across large healthcare networks.

As healthcare increasingly embraces artificial intelligence and data-driven diagnostics, companies that can integrate advanced analytics into existing clinical workflows may benefit from significant long-term Demand.

CT:VQ Represents a Potentially Transformational Opportunity

A major component of the 4DMedical Investment story revolves around CT:VQ, one of the company's most advanced imaging solutions.

The technology enables quantitative ventilation and perfusion analysis using routine non-contrast CT scans, allowing clinicians to assess lung function without requiring nuclear medicine procedures or contrast agents.

This capability has already positioned CT:VQ as an alternative within the traditional ventilation-perfusion imaging market. However, management believes the larger opportunity lies beyond this existing segment.

Recent clinical initiatives are targeting the pulmonary embolism (PE) market, a major area of emergency medicine where millions of CT scans are performed annually in the United States. Pulmonary embolism remains a serious cardiovascular condition that can be difficult to diagnose due to non-specific symptoms such as chest pain and shortness of breath.

To support expansion into this market, the company launched the CLEAR clinical evidence program. The initiative includes a multinational study comparing CT:VQ directly against current standard-of-care imaging techniques in patients with suspected pulmonary embolism.

The program is being led by institutions within the Mass General Brigham network, including Massachusetts General Hospital, one of the world's most recognised academic medical centres.

If successful, the initiative could significantly expand CT:VQ adoption opportunities. Management estimates that the obtainable U.S. market for CT:VQ could increase to approximately US$3 billion annually, creating a substantially larger commercial opportunity than the company's original Target market.

Commercial Momentum Continues to Build in the United States

While technological innovation is important, long-term investors often focus on commercial adoption as a key indicator of future success.

One of the most notable recent developments for 4DMedical has been the commercial agreement with SimonMed Imaging, one of the largest outpatient imaging providers in the United States.

SimonMed operates more than 170 imaging centres across 10 states and employs a network of more than 300 radiologists. Under the agreement, SimonMed will deploy CT:VQ and LDAf solutions across its network under a commercial arrangement from day one.

The significance of this development extends beyond the immediate financial contribution. Adoption by a large-scale imaging provider provides validation of the technology's clinical Utility and demonstrates growing confidence among healthcare organisations.

The Partnership is also expected to contribute to reimbursement evidence generation, which remains a critical Factor in broader healthcare adoption. Reimbursement pathways often play an important role in determining the speed at which medical technologies achieve widespread commercial success.

For investors, expanding deployment across major healthcare networks may represent an important step toward recurring software Revenue growth.

European Expansion Creates a New Growth Engine

Another major milestone in 4DMedical's growth strategy is its expansion into Europe through the Acquisition of Austrian medical technology company contextflow.

Rather than building a European presence from scratch, the acquisition provides immediate access to commercial infrastructure, regulatory capabilities, clinical relationships and an established customer base.

Europe represents one of the world's largest healthcare markets, with significant demand for respiratory diagnostics and increasing focus on lung cancer screening programs. Management estimates the addressable respiratory and thoracic imaging opportunity in Europe at approximately US$1.5 billion to US$2 billion.

The transaction was structured to be Capital efficient, involving an upfront cash payment of approximately A$18.56 million plus performance-based incentives. The acquisition also includes approximately A$30.8 million in accumulated tax losses, potentially enhancing future economic value.

Beyond geographic expansion, contextflow contributes complementary artificial intelligence technology focused on lung cancer detection and thoracic imaging analysis. These capabilities broaden 4DMedical's product portfolio and support its ambition to offer a more comprehensive lung health solution.

The combination of structural imaging, functional assessment and AI-driven analytics may strengthen the company's competitive position as healthcare providers increasingly seek integrated diagnostic solutions.

Why Investors Are Paying Attention to 4DMedical

Several factors continue to attract investor interest in 4DMedical.

First, the company operates within large and growing healthcare markets where unmet clinical needs remain significant. Respiratory disease, lung cancer and pulmonary embolism collectively represent substantial global healthcare burdens.

Second, the business has demonstrated an ability to secure regulatory clearances, establish clinical partnerships and win commercial contracts with major healthcare organisations.

Third, the company is expanding internationally across three major regions—Australia and New Zealand, North America and Europe—creating multiple pathways for future growth.

Finally, artificial intelligence continues to gain prominence within healthcare, and 4DMedical's combination of imaging software, AI capabilities and SaaS delivery aligns with several long-term industry trends.

While healthcare technology businesses often face adoption, reimbursement and execution risks, investors are increasingly monitoring companies capable of combining innovative technology with growing commercial traction.

Share Price Performance

4DMedical shares closed at $3.92 on 4 June 2026, finishing the session 3.43% higher.

Despite the positive daily performance, the stock remains down approximately 4.16% over the past month. However, the longer-term picture is considerably stronger, with shares delivering an extraordinary gain of approximately 1,164.52% over the past year.

The company currently has a Market Capitalisation of approximately $2.25 billion, reflecting the significant increase in investor interest surrounding its technology platform and growth prospects.

Trading activity also remained healthy, with approximately 5.42 million shares changing hands during the latest session.

While share price performance alone does not determine investment quality, the substantial appreciation over the past year highlights growing market confidence in the company's commercial progress, expanding addressable markets and international growth strategy.

Conclusion

4DMedical has positioned itself at the intersection of healthcare, artificial intelligence and advanced medical imaging. Through its proprietary lung analysis technologies, expanding commercial partnerships and growing international footprint, the company is seeking to redefine how respiratory disease is detected, assessed and monitored.

Recent developments have significantly broadened the company's opportunity set. The expansion of CT:VQ into the pulmonary embolism market, commercial deployment through SimonMed, and entry into Europe through the contextflow acquisition collectively strengthen the long-term growth narrative.

Although healthcare technology companies face execution challenges and regulatory complexities, 4DMedical has demonstrated meaningful progress in building a global platform capable of addressing large and growing healthcare markets. As respiratory health remains a critical area of medical focus worldwide, investors are likely to continue watching closely as the company advances its commercialisation strategy.